AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7528310 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding blood containing NANB surrogate positive units
Number of subjects: 4588
Study 7528310 — intervention group
Group type: COMPARATOR
Intervention: No withholding of blood containing NANB surrogate positive units
Number of subjects: 4588
Study 7528310 — intervention group
Group type: EXPERIMENTAL
Intervention: Syngeneic blood (non-randomised cohort)
Number of subjects: 4588
Study 2687198 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiray 320 mg I/mL
Number of subjects: 60
Study 2687198 — intervention group
Group type: COMPARATOR
Intervention: Omnipaque 300 mg I/mL
Number of subjects: 60
Study 30891748 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized and progressive multicomponent exercise at moderate intensity for 6 months
Number of subjects: 112
Study 28501679 — intervention group
Group type: EXPERIMENTAL
Intervention: specialist depression team arm
Number of subjects: 187
Study 28501679 — intervention group
Group type: COMPARATOR
Intervention: general mental health arm
Number of subjects: 187
Study 25338833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided antegrade CFA puncture
Number of subjects: 100
Study 25338833 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-assisted antegrade CFA puncture
Number of subjects: 100
Study 23107599 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 14
Study 23107599 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 14
Study 21616596 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (verum acupuncture plus placebo)
Number of subjects: 140
Study 21616596 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus flunarizine (Control)
Number of subjects: 140
Study 18452199 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab initiation
Number of subjects: 494
Study 18452199 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 494
Study 18452199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infliximab)
Number of subjects: 494
Study 17130196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 741
Study 17130196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 741
Study 17130196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 741
Study 12963704 — intervention group
Group type: COMPARATOR
Intervention: FU + LV (bolus FU 425 mg/m2 + LV 20 mg/m2 on days 1 to 5, repeated on day 28)
Number of subjects: 497
Study 12963704 — intervention group
Group type: EXPERIMENTAL
Intervention: FU24h (FU 2600 mg/m2 as a 24-hour infusion)
Number of subjects: 497
Study 12963704 — intervention group
Group type: EXPERIMENTAL
Intervention: FU24h + LV (FU 2600 mg/m2 as a 24-hour infusion + LV 500 mg/m2)
Number of subjects: 497
Study 12963704 — intervention group
Group type: EXPERIMENTAL
Intervention: FU24h + LV
Number of subjects: 497
Study 12963704 — intervention group
Group type: COMPARATOR
Intervention: FU + LV
Number of subjects: 497
Study 12963704 — intervention group
Group type: EXPERIMENTAL
Intervention: FU24h
Number of subjects: 497
Study 12963704 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 497
Study 10792163 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-sitosterol treatment continued for 18 months (38 patients)
Number of subjects: 117
Study 10792163 — intervention group
Group type: EXPERIMENTAL
Intervention: No further therapy after beta-sitosterol (41 patients)
Number of subjects: 117
Study 10792163 — intervention group
Group type: COMPARATOR
Intervention: Beta-sitosterol treatment started after placebo (27 patients)
Number of subjects: 117
Study 10792163 — intervention group
Group type: COMPARATOR
Intervention: No further therapy after placebo (18 patients)
Number of subjects: 117
Study 9076206 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 8472740 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 30
Study 8472740 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 30
Study 8472740 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 30
Study 3888239 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol pretreatment (0.5 mg kg‐1 bolus followed by 0.1 mg kg‐1 h‐1 infusion)
Number of subjects: 30
Study 3888239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31375651 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 228
Study 29941810 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (4 mg capsule)
Number of subjects: 23
Study 29941810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 26467417 — intervention group
Group type: EXPERIMENTAL
Intervention: Land exercise
Number of subjects: 53
Study 26467417 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise
Number of subjects: 53
Study 26467417 — intervention group
Group type: COMPARATOR
Intervention: No-exercise
Number of subjects: 53
Study 24549687 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Choice Testing (FCT)
Number of subjects: 64
Study 24549687 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cognitive Interviewing (MCI)
Number of subjects: 64
Study 24549687 — intervention group
Group type: EXPERIMENTAL
Intervention: FCT paired with MCI
Number of subjects: 64
Study 24549687 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical Implicit Association Testing (aIAT)
Number of subjects: 64
Study 22968615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with antibiotics and superlimf
Number of subjects: 0
Study 22968615 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with antibiotics
Number of subjects: 0
Study 20368400 — intervention group
Group type: EXPERIMENTAL
Intervention: Genius dialysis
Number of subjects: 15
Study 20368400 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hemodialysis
Number of subjects: 15
Study 20368400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 15
Study 20368400 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 15
Study 18547224 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 40
Study 18547224 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 40
Study 16060202 — intervention group
Group type: EXPERIMENTAL
Intervention: Piper methysticum 30C
Number of subjects: 31
Study 16060202 — intervention group
Group type: EXPERIMENTAL
Intervention: Plumbum metallicum 30C
Number of subjects: 31
Study 16060202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12161978 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treated group
Number of subjects: 10
Study 12161978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 10528604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vasopressin (VP) at 0.04 U/min
Number of subjects: 10
Study 10528604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10707717 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine (75 mg bid)
Number of subjects: 53
Study 10707717 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg bid)
Number of subjects: 53
Study 2183710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (750 mg twice a day)
Number of subjects: 59
Study 2183710 — intervention group
Group type: COMPARATOR
Intervention: Intravenous broad-spectrum cephalosporin or nafcillin-aminoglycoside combination
Number of subjects: 59
Study 2183710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 59
Study 2183710 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 59
Study 6119933 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular narcotic analgesic ketobemidone
Number of subjects: 90
Study 6119933 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine‐epinephrine intercostal nerve block
Number of subjects: 90
Study 6119933 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (4 mg)
Number of subjects: 90
Study 31689905 — intervention group
Group type: EXPERIMENTAL
Intervention: Educator-led daily Energisers (3 brief 5-minute sessions each day)
Number of subjects: 14
Study 31689905 — intervention group
Group type: COMPARATOR
Intervention: Normal practice in control ECEC centres
Number of subjects: 14
Study 29040538 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min of supine immobilization after IUI
Number of subjects: 498
Study 29040538 — intervention group
Group type: COMPARATOR
Intervention: Immediate mobilization after IUI
Number of subjects: 498
Study 25889322 — intervention group
Group type: EXPERIMENTAL
Intervention: Durolane (3.0 ml injection at week 0)
Number of subjects: 349
Study 25889322 — intervention group
Group type: COMPARATOR
Intervention: Artz (five 2.5 ml injections at weeks 0, 1, 2, 3, and 4)
Number of subjects: 349
Study 25889322 — intervention group
Group type: COMPARATOR
Intervention: Artz
Number of subjects: 349
Study 25889322 — intervention group
Group type: EXPERIMENTAL
Intervention: Durolane
Number of subjects: 349
Study 24917003 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) 22.5 mg subcutaneously
Number of subjects: 12
Study 24917003 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) 30 mg subcutaneously
Number of subjects: 12
Study 24917003 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-144-SR (6M) administered intramuscularly
Number of subjects: 12
Study 23040735 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-digit CPT
Number of subjects: 0
Study 23040735 — intervention group
Group type: COMPARATOR
Intervention: 2-digit CPT
Number of subjects: 0
Study 23040735 — intervention group
Group type: COMPARATOR
Intervention: 4-digit CPT
Number of subjects: 0
Study 23040735 — intervention group
Group type: COMPARATOR
Intervention: Shapes CPT
Number of subjects: 0
Study 19863831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation/exsufflation
Number of subjects: 8
Study 19863831 — intervention group
Group type: COMPARATOR
Intervention: Current physiotherapy practice without in‐exsufflation
Number of subjects: 8
Study 17070743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest with supine treadmill exercise within lower body negative pressure (LBNP)
Number of subjects: 14
Study 17070743 — intervention group
Group type: COMPARATOR
Intervention: Sedentary bed rest (control)
Number of subjects: 14
Study 17070743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest with supine treadmill exercise within LBNP
Number of subjects: 14
Study 15279525 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance established early in treatment
Number of subjects: 0
Study 15279525 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation capacity during Phase 2 exposure therapy
Number of subjects: 0
Study 11521689 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional optic disc algorithm applied to Topcon Image-net
Number of subjects: 100
Study 11521689 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 100
Study 9691877 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Unique
Number of subjects: 100
Study 9691877 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 100
Study 7871661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic block (subpleural and stellate ganglion blocks)
Number of subjects: 50
Study 7871661 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding initiated early after pain relief
Number of subjects: 50
Study 7871661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic block and early enteral feeding
Number of subjects: 50
Study 3281431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin after early thrombolysis
Number of subjects: 0
Study 3281431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31466119 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib ointment 30 mg g-1
Number of subjects: 91
Study 31466119 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 91
Study 31466119 — intervention group
Group type: COMPARATOR
Intervention: Delgocitinib ointment 30 mg g-1 and Vehicle ointment
Number of subjects: 91
Study 30419113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime ASCVD risk (50% lifetime ASCVD event risk)
Number of subjects: 2708
Study 30419113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year ASCVD event risk (15% 10-year ASCVD event risk)
Number of subjects: 2708
Study 30419113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year CVD death risk (4% 10-year cardiovascular disease death risk)
Number of subjects: 2708
Study 30419113 — intervention group
Group type: COMPARATOR
Intervention: Pictogram risk display
Number of subjects: 2708
Study 30419113 — intervention group
Group type: COMPARATOR
Intervention: Bar graph risk display
Number of subjects: 2708
Study 30419113 — intervention group
Group type: COMPARATOR
Intervention: No graphic risk display
Number of subjects: 2708
Study 28113021 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Tablets (100 µg)
Number of subjects: 114
Study 28113021 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Morphine (5 mg)
Number of subjects: 114
Study 26271059 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 7364
Study 26271059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7364
Study 24156640 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 576
Study 24156640 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 576
Study 24156640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800 mg
Number of subjects: 576
Study 24156640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 21138561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity, home-based, self-management physical activity program
Number of subjects: 360
Study 21138561 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, structured, supervised exercise program
Number of subjects: 360
Study 21138561 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 18240230 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFalpha antagonists
Number of subjects: 3
Study 18240230 — intervention group
Group type: COMPARATOR
Intervention: No TNFalpha antagonists
Number of subjects: 3
Study 18240230 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3
Study 17040151 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 184
Study 17040151 — intervention group
Group type: COMPARATOR
Intervention: Palliative care
Number of subjects: 184
Study 17040151 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care (staff)
Number of subjects: 184
Study 17040151 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (staff)
Number of subjects: 184
Study 12723463 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg almotriptan with 400 mg ketoconazole once daily
Number of subjects: 16
Study 12723463 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg almotriptan alone
Number of subjects: 16
Study 11102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefradafiban 30 mg
Number of subjects: 531
Study 11102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefradafiban 20 mg
Number of subjects: 531
Study 11102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefradafiban 45 mg
Number of subjects: 531
Study 11102255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study 11102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefradafiban (all doses)
Number of subjects: 531
Study 9297998 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic methotrexate (four 1.0 mg/kg doses of intramuscular methotrexate alternated with 0.1 mg/kg oral folinic acid)
Number of subjects: 100
Study 9297998 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingostomy
Number of subjects: 100
Study 7688379 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (12 IU/day x 12 days) with HMG/buserelin
Number of subjects: 40
Study 7688379 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with HMG
Number of subjects: 40
Study 3472476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus diflunisal
Number of subjects: 48
Study 3472476 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 48
Study 3472476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29330620 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg
Number of subjects: 0
Study 29330620 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 40 mg
Number of subjects: 0
Study 29330620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27733151 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber (10.5 g daily)
Number of subjects: 40
Study 27733151 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 40
Study 23635882 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with higher levels of social anxiety
Number of subjects: 161
Study 23635882 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative performance expectations and self-focused attention
Number of subjects: 161
Study 23698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (COC) and progestin‐only pills (POP)
Number of subjects: 4913
Study 23698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception
Number of subjects: 4913
Study 23698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception (unweighted site‐adjusted model)
Number of subjects: 4913
Study 23698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception (baseline factor adjusted model)
Number of subjects: 4913
Study 20144259 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based multi-component education intervention
Number of subjects: 579
Study 20144259 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 579
Study 19061734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-didactic treatment
Number of subjects: 360
Study 19061734 — intervention group
Group type: COMPARATOR
Intervention: Functional-experiential treatment
Number of subjects: 360
Study 19061734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-didactic treatment (younger participants)
Number of subjects: 360
Study 19061734 — intervention group
Group type: COMPARATOR
Intervention: Functional-experiential treatment (participants older than 30 years)
Number of subjects: 360
Study 19061734 — intervention group
Group type: COMPARATOR
Intervention: Functional-experiential treatment (participants with more years of education)
Number of subjects: 360
Study 16181531 — intervention group
Group type: EXPERIMENTAL
Intervention: Quyu Xiaoban Capsule (QYXB) and conventional medicine
Number of subjects: 80
Study 16181531 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine alone
Number of subjects: 80
Study 12562408 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (50 mg x kg(‐1))
Number of subjects: 24
Study 12562408 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 24
Study 10562780 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic tape (TT)
Number of subjects: 70
Study 10562780 — intervention group
Group type: COMPARATOR
Intervention: Comparison tape (CT)
Number of subjects: 70
Study 8546093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin intervention for coronary restenosis, specific dosage and duration not available
Number of subjects: 0
Study 8546093 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 1870249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive HIV/AIDS intervention program (up to 30 sessions)
Number of subjects: 145
Study 1870249 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 145
Study 6855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorophenamide
Number of subjects: 3
Study 31485980 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strips
Number of subjects: 0
Study 31485980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30380530 — intervention group
Group type: COMPARATOR
Intervention: Oral steroid + intratympanic steroid injection (ITSI) (Control group)
Number of subjects: 60
Study 30380530 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid + ITSI + Hyperbaric Oxygen Therapy (HBOT) (Study group)
Number of subjects: 60
Study 30380530 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid + ITSI + HBOT (Study group)
Number of subjects: 60
Study 26104243 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium adherence to Mediterranean diet
Number of subjects: 3042
Study 26104243 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet
Number of subjects: 3042
Study 26104243 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to Mediterranean diet
Number of subjects: 3042
Study 26104243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 3042
Study 26104243 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain cereals, fruits, and legumes
Number of subjects: 3042
Study 24555904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipotoxin (80 mg liposomes and 200 U BoNT‐A)
Number of subjects: 24
Study 24555904 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (N/S)
Number of subjects: 24
Study 21263014 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel formulation of C1 esterase inhibitor concentrate
Number of subjects: 13
Study 21263014 — intervention group
Group type: COMPARATOR
Intervention: Reference product of C1 esterase inhibitor concentrate
Number of subjects: 13